Anti-Calicheamicin payload antibody in PK study in ADC drug development

Anti-calicheamicin antibodies play an important role in PK investigations to determine adequately the concentrations of calicheamicin and its conjugates in biological matrices. Calicheamicin is a very toxic antibiotics which have been employed as effector moiety in ADCs for the targeted delivery of cancer chemotherapy. This is due to the fact that calicheamicin can lead to double stranded DNA breaks and hence cell death in the tumor cells.

**Product list of GeneMedi's anti-Calicheamicin antibody**
Cat No.	Product Description	Fc	Products Information
GTU-Bios-Calicheamicin-Ab	Anti-Calicheamicin-monoclonal-antibody (mAb)	hFc/mFc	Details

All Payloads of ADCs

Application

Competitive immunoassay validation (CompetitiveELISA) and other Immunoassay,
PK & PD assay for MMAE payload of Antibody-drug Conjugate (ADC)

Highlight:

Purity: ≥95% (SDS-PAGE)
High affinityand specificity validated
High sensitivity verified by ADCs binding assay

Application
Technical Resource

Why Use Anti-Calicheamicin Antibody in ADC drug development?

Specificity: Specific anti-calicheamicin antibodies on the other hand, are designed to attach itself to calicheamicin as well as its closely related compounds. Such quantification is crucial in assaying the extent of calicheamicin in an ADC construct relative to other substances present in the formulation or inside the body.
Sensitivity: Because of the extreme toxicity and stability/potency of calicheamicin, these antibodies require high specificity to be able to detect very low concentrations of the drug. That capability is important for managing the therapeutic levels and risks of toxicity so that the drug is on target but not too close to dangerous levels.
Understanding ADC Dynamics: Employing anti-calicheamicin antibodies enables the researchers to observe the stability of the calicheamicin-ADC conjugate, change in the number of unconjugated calicheamicin, percentage of free drug as well as the total amount of the drug. This information is necessary to evaluate exposure and effect profile with cancer cells, as well as the elimination of the drug from the system.

How to use Anti-Calicheamicin Antibody in ADC drug development?

Development of Immunoassays: These antibodies are employed in the development of immunoassay techniques, for example enzyme-linked immunosorbent assay (ELISA), that can be used in determining the amount of calicheamicin in organisms fluids such as blood, plasma and possibly tissues. These assays are necessary for determining the pharmacokinetics of calicheamicin like absrote, distribution, metabolism and excretion among others.
Sample Collection and Analysis: In other words, in a PK study, blood samples are withdrawn at different time points after the administration of the calicheamicin-ADC. These samples are then assayed using the developed immunoassays that involve the use of anti-calicheamicin antibodies to quantitate the associated as well as the unbound calicheamicin.
Data Interpretation and Clinical Application: The data generated from these assays shed light on aspects of the pharmacokinetic property of calicheamicin. Such data is invaluable specifically for the modulation of dosage regimens and reduction of toxic manifestations in the framework of ADC therapy enhancement.

Since anti-calicheamicin antibodies are critical for PK studies, their use can be considered as basic for the further development of ADC-based on calicheamicin and their further application in the clinical practice. These studies help to establish the foundation of treatment regimens which are informed of correct and accurate pharmacokinetic data in an effort to offer safer and efficient therapies for cancer.